Curis Announces Additional Data from TakeAim Leukemia Study
Press Releases
Curis, Inc.  
December 10, 2024

Curis Announces Additional Data from TakeAim Leukemia Study

LEXINGTON, Mass., Dec. 10, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, yesterday

avatar profile Olean Times Herald

Olean Times Herald


Local & Social